Cost-Effectiveness of brca1 and brca2 mutation testing to target parp inhibitor use in platinum-sensitive recurrent ovarian cancer

International Journal of Gynecological Cancer

Volumn 23, Issue 5, 2013, Pages 846-852

  Secord, Angeles Alvarez ^a   Barnett, Jason Cory ^b   Ledermann, Jonathan A ^c   Peterson, Bercedis L ^d   Myers, Evan R ^a   Havrilesky, Laura J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Department of Biostatistics and Bioinformatics ^*  (United States)

Author keywords

Biomarkers; Cost effectiveness; Ovarian cancer; PARP inhibitors

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; DASATINIB; DOXORUBICIN; ERLOTINIB; IMATINIB; LAPATINIB; OLAPARIB; PLATINUM COMPLEX; SORAFENIB; SUNITINIB;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DISEASE CARRIER; DRUG COST; DRUG USE; FEMALE; GENE MUTATION; HAZARD RATIO; HEART FAILURE; HIDDEN MARKOV MODEL; HUMAN; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY ANALYSIS; VOMITING;

ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MUTATION; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; PLATINUM; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; SURVIVAL RATE;

EID: 84880430943     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31829527bd     Document Type: Article

References (32)

1. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: Targeted therapies in ovarian cancer. Nat Rev Cancer. 2009;9:167-181.
2. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A. 2011;108:3406-3411.
3. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-134.
4. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28:2512-2519.
5. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852-861.
6. Audeh MW, Carmichael J, Penson RT, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet. 2010;376:245-251.
7. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382-1392.
8. AMC D, Oaknin A, Poole CJ, et al. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study. J Clin Oncol. 2012;20:a5001.
9. Cohn DE, Kim KH, Resnick KE, et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol. 2011;29:1247-1251.
10. Mittmann N, Au HJ, Tu D, et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst. 2009;101:1182-1192.
11. Shankaran V, Bentrem DJ, Mulcahy MF, et al. Economic Implications of Kras Testing in Metastatic Colorectal Cancer (mCRC). American Society of Clinical Oncology, Gastrointestinal Cancers Symposium; Abstract 298: January 15-17, 2009, San Francisco.
12. Ferrusi IL, Marshall DA, Kulin NA, et al. Looking back at 10 years of trastuzumab therapy: What is the role of HER2 testing? A systematic review of health economic analyses. Per Med. 2009;6:193-215.
13. Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: Relationship to family history and implications for genetic testing. Am J Obstet Gynecol. 1998;178:670-677.
14. Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615.
15. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654-2663.
16. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98:1694-1706.
17. Pyenson B, Connor S, Fitch K, et al. Medicare cost in matched hospice and non-hospice cohorts. J Pain Symptom Manage. 2004;28:200-210.
18. U.S. Department of Health & Human Services: CMS: Centers for Medicare and Medicaid Services Web site. Available at: Http://www.cms.gov/apps/ physician-fee-schedule/license-agreement.aspx. Accessed October 1, 2012.
19. Red Book, Pharmacy's Fundamental Reference. 114th ed. Montvale, Physicians' Desk Reference, Inc; PDR Network, LLC, Montvale, NJ, 2010.
20. States Department of Labor. Consumer Price Index Web site. Available at: Http://www.bls.gov/cpi/. Accessed October 1, 2012.
21. Tom's Inflation Calculator Web site. Available at: Http://www.halfhill. com/inflation.html, Accessed October 1, 2012.
22. Department of Health & Human Services: Agency for Healthcare Research and Quality Web site. Available at: Http://hcupnet.ahrq.gov. Accessed October 1, 2012.
23. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-5186.
24. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010; 117:497-504.
25. Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007; 25:625-633.
26. Helwick C. Personalizing Cancer Care is Everyone's Mission; The economics of personalized medicine in oncology; Pretreatment biomarker testing indisputable in colorectal cancer. ASCO 2009;Payers Perspectives. American Health & Drug Benefits. 2009;2(5):1, 3.
27. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091-2096.
28. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25: 5287-5312.
29. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43.
30. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108:18032-18037.
31. University of Washington Laboratory Medicine Clinical Test Information: BROCAVCancer Risk Panel Web site. Available at: Http://web.labmed.washington. edu/tests/genetics/BROCA. Accessed November 25, 2013.
32. Wang X, Weaver DT. The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am J Cancer Res. 2011;1:301-327.